Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunshine Biopharma has released results from its cytotoxicity study of Adva-27a in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.
Subscribe to our email newsletter
The results of the trial suggested that Adva-27 is 16-times more effective at killing Multidrug Resistant Breast Cancer cells in comparison to Etoposide.
Additionally, the data from the trial proved that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.
Sunshine president and CEO Steve Slilaty said Adva-27a now offers a chemical structure which can be used as a basis for studying the mechanism of action of P-Glycoprotein as well as for the development of new drugs which can overcome the resistance caused by P-Glycoprotein and similar enzymes.